AngioDynamics Reports Fiscal 2020 Third Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
AngioDynamics (ANGO) Tops Q3 EPS by 4c, Revenues Beat
April 7, 2020 7:02 AM EDTAngioDynamics (NASDAQ: ANGO) reported Q3 EPS of $0.01, $0.04 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $69.8 million versus the consensus estimate of $68.55 million.
Third Quarter 2020 Financial Results
Net sales for the third quarter of fiscal 2020 were $69.8 million, an increase of 6.5% compared to the prior-year quarter. Excluding the impact of Asclera sales, which were discontinued during fiscal year 2019, net sales grew 9.3% year over year. Foreign currency translation did not have a significant impact on the Companys sales in the quarter.
Oncology net sales were $14.6 million, an... More